@R_H_Ebright @jakewinter108 @mbeisen@nature@LabMassague I feel like part of the lag time is due to the increase in the amount of data a reviewer need to comb through to validate the science.
We are thrilled to announce that @arkudatx has secured a $44M Series A to discover therapies with the potential to change the trajectory of neurodegenerative disease, starting with GRN-related frontotemporal dementia (FTD-GRN) #progranulin#FTD#endFTD. https://t.co/m7yCL3uFDz